Arkansas weight loss treatment prescribed online
Compounded Tirzepatide Injections for $329 per month
Weight loss, simplified.
How it works
Fill out our questionnaire
Answer a few questions to ensure you are a good fit for treatment.
Book your appointment
We offer convenient time slots, seven days per week for your busy routine!
Meet your provider
On the day of your appointment, chat with an Arkansas-based provider online and, if you qualify, your prescription will be sent same-day to a licensed compounding pharmacy.
Begin your journey
Once processed, your medicine will be shipped overnight straight to your door.
Reach out any time
Your membership includes messaging with your provider, and appointments to discuss your progress or concerns.
Refill
After an appropriate time, based on your specific treatment, we will reach out to you to start the follow-up process and get your subsequent refills.
Frequently asked questions
Simply email us at support@mavismeds.com. We will cancel your membership and you will see no further billing.
We’ve prioritized low costs for Arkansans, and have worked very hard to keep our pricing at the lowest possible point. As a result, we’re only able to refund for change-of-heart scenarios, prior to meeting with a provider. If you have any refund or cancellation questions, please email us at support@mavismeds.com
More information
Success for patients using Tirzepatide can be transformative, encompassing significant weight loss, improved metabolic health, and enhanced quality of life. Tirzepatide, a dual GIP and GLP-1 receptor agonist, offers a unique approach to weight management and diabetes care. For patients embarking on a long-term Tirzepatide regimen, the journey typically begins with a notable reduction in appetite and better control over food cravings. This leads to a decrease in caloric intake and healthier eating habits.
*Over several months, patients can expect substantial weight loss. Clinical trials have demonstrated that Tirzepatide can lead to an average weight reduction of up to 22.5% of body weight, which is higher than many other weight loss medications. Tirzepatide use has been shown to lower blood pressure, improve cholesterol levels, and leads to better blood sugar control, significantly reducing the risk of cardiovascular diseases and type 2 diabetes. Patients also report increased energy levels and improved physical mobility, enabling a more active lifestyle and further supporting weight management goals.
Tirzepatide’s effects extend beyond weight loss. Patients often experience better glycemic control, which is particularly beneficial for those with type 2 diabetes. The medication helps regulate blood sugar levels more effectively, reducing the need for additional diabetes medications and enhancing overall health.
Tirzepatide differs from Semaglutide in its mechanism of action. While Semaglutide is a GLP-1 receptor agonist that mimics the effects of the GLP-1 hormone to regulate appetite and insulin response, Tirzepatide acts on both the GIP and GLP-1 receptors. This dual action not only enhances appetite regulation and insulin secretion but also improves insulin sensitivity and glucose metabolism more effectively. Consequently, Tirzepatide offers higher average weight loss and glycemic control outcomes compared to Semaglutide, making it a highly effective option for patients seeking comprehensive metabolic improvements.
Patients using Tirzepatide can expect, on average, to achieve significant weight loss, improved metabolic health, and a higher quality of life.
Mavis, LLC is a patient management platform designed to assist independent physicians and practitioners who use our system to deliver services. We do not directly offer medical or pharmacy services, and payment through our platform does not ensure the issuance or fulfillment of a prescription. Medical services are provided by independent practitioners. The information on this website is intended for informational purposes only and should not replace professional medical advice, diagnosis, or treatment.
This site is an advertisement for our services and does not promote any specific medication. *Disclaimer: FDA-approved medications such as Saxenda®, Victoza®, Wegovy®, and Ozempic® are owned by Novo Nordisk™, and Mounjaro™ is produced by Eli Lilly and Company™. Mavis, LLC is not affiliated with or endorsed by these companies or their products and does not provide these medications.